2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent VERU-111, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | Phase 3 | Terminated | Veru Inc. | 105 | 2021-06-24 | 2024-02-05 |
| Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer Tasquinimod, Placebo - Prostatic Neoplasms, Castration-Resistant | Phase 3 | Terminated | Ipsen | 146 | 2014-01-01 | 2021-04-23 |
Neoplasm Metastasis (1) · Prostatic Neoplasms (1)
Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Prostatic Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Prostatic Neoplasms (1)
Abiraterone Acetate (1) · abiraterone (1) · enzalutamide (1) · sabizabulin (1) · tasquinimod (1)
China (1) · South Korea (1) · Taiwan (1) · United States (1)